Teva Pharmaceutical Industries Ltd.

TEVA

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000818686

C/D

on the C/D boundary of 370 graded peers in healthcare

rank 226 of 370; percentile 61.0; sampling error 2.5 points; lower is stronger



C/D, the tortoise



Scoreboard


Profitability	C	percentile 56.6
Solvency	C	percentile 48.5
Growth and financing	C	percentile 50.9
Reliability	0.94 AUC	filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets	total assets $40.7B
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	none triggered	not computable: distress
Inputs computable	9 of 14	
Graded from	filings received through Feb 3, 2026	276 days before the rescan; latest periodic filing 10-Q received Nov 3, 2026
Last close	$41.77	2026-11-05; market equity $48.7B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 3, 2026

We continue to monitor these legislative developments and evaluate their impacts on us and whether any changes to our business practices and operations are necessary in order to comply with such legislative reforms. However, we cannot accurately predict the ultimate impact of such legislative developments on our business or whether additional changes in regulatory policies will occur in the future. We have experienced, and may continue to experience, delays in launches of our new generic products.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 56.6						
Gross profitability	21.9%	32.3%		61.5	365	2025-12-31
Return on invested capital	not computable	9.3%				
required facts have no common fiscal period end						
Accruals ratio	(0.6%)	(6.6%)		79.5	802	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	1.7 pts	2.8 pts		28.6	242	2025-12-31
Solvency, sleeve percentile 48.5						
Twelve-month failure probability	not computable	0.07%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(0.41)	(0.37)		38.3	747	2025-12-31
Net debt to EBITDA	not computable	1.82x				
required facts have no common fiscal period end						
Interest coverage	2.35x	(4.51x)		18.2	78	2025-12-31
Current ratio	1.04x	2.94x		88.9	828	2025-12-31
Growth and financing, sleeve percentile 50.9						
Revenue growth, three-year compound	5.0%	10.0%		60.8	412	2025-12-31
Free cash flow growth, three-year compound	3.3%	10.9%		64.2	96	2025-12-31
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	not computable	2.2%				
four consecutive annual observations are required						
Net share issuance, one year	1.4%	2.5%		27.7	630	2025-12-31

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
221	Mannkind Corp. (MNKD)	59.6	C/D	
222	GeneDx Holdings Corp. (WGS)	59.9	C/D	fortress balance sheet
223	Labcorp Holdings Inc. (LH)	60.2	C/D	
224	Amylyx Pharmaceuticals, Inc. (AMLX)	60.4	C/D	degenerate inputs
225	Twist Bioscience Corp. (TWST)	60.7	C/D	fortress balance sheet
226	Teva Pharmaceutical Industries Ltd. (TEVA)	61.0	C/D	
227	Akebia Therapeutics, Inc. (AKBA)	61.2	C/D	fortress balance sheet
228	ARS Pharmaceuticals, Inc. (SPRY)	61.5	C/D	short runway, distress
229	Embecta Corp. (EMBC)	61.8	C/D	late filer
230	Biogen Inc. (BIIB)	62.1	C/D	
231	Beam Therapeutics Inc. (BEAM)	62.3	C/D	

What the price implies

at the 2026-11-05 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	93.4%	(2.1%)	89
Distance from 52-week high	(0.7%)	(30.4%)	95
EBIT to enterprise value	2.9%	(1.5%)	66
Free cash flow yield	2.4%	(1.0%)	67
Book value to price	0.16	0.29	35
Sales to price	0.35	0.30	55

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	6.2%	21.4%	34
Relative strength against the sector, log excess return	0.49	(0.19)	89

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$4.1B
Operating cash flow, four quarters	$1.8B
Months of runway	not finite
Days since last periodic filing	3 (10-Q received Nov 3, 2026)
Median daily dollar volume, 63 sessions	$213.7M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$8.9B	2025-12-31	2026-02-03	10-K	26-034532
2	assets	us-gaap:Assets	$40.7B	2025-12-31	2026-02-03	10-K	26-034532
3	net income	us-gaap:NetIncomeLoss	$1.4B	2025-12-31	2026-02-03	10-K	26-034532
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.6B	2025-12-31	2026-02-03	10-K	26-034532
5	assets	us-gaap:Assets	$39.3B	2024-12-31	2026-02-03	10-K	26-034532
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$17.3B	2025-12-31	2026-02-03	10-K	26-034532
7	gross profit	us-gaap:GrossProfit	$8.1B	2024-12-31	2026-02-03	10-K	26-034532
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$16.5B	2024-12-31	2026-02-03	10-K	26-034532
9	gross profit	us-gaap:GrossProfit	$7.6B	2023-12-31	2026-02-03	10-K	26-034532
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$15.8B	2023-12-31	2026-02-03	10-K	26-034532
11	gross profit	us-gaap:GrossProfit	$7.0B	2022-12-31	2025-02-05	10-K	25-020826
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$14.9B	2022-12-31	2025-02-05	10-K	25-020826
13	gross profit	us-gaap:GrossProfit	$7.6B	2021-12-31	2024-02-12	10-K	24-031005
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$15.9B	2021-12-31	2024-02-12	10-K	24-031005
15	current assets	us-gaap:AssetsCurrent	$13.9B	2025-12-31	2026-02-03	10-K	26-034532
16	current liabilities	us-gaap:LiabilitiesCurrent	$13.5B	2025-12-31	2026-02-03	10-K	26-034532
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$13.8B	2025-12-31	2026-02-03	10-K	26-034532
18	operating income	us-gaap:OperatingIncomeLoss	$2.2B	2025-12-31	2026-02-03	10-K	26-034532
19	book equity	us-gaap:StockholdersEquity	$7.9B	2025-12-31	2026-02-03	10-K	26-034532
20	liabilities	us-gaap:Liabilities	$32.8B	2025-12-31	2026-02-03	10-K	26-034532
21	interest expense	us-gaap:InterestExpense	$916.0M	2025-12-31	2026-02-03	10-K	26-034532
22	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$501.0M	2025-12-31	2026-02-03	10-K	26-034532
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.2B	2024-12-31	2026-02-03	10-K	26-034532
24	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$498.0M	2024-12-31	2026-02-03	10-K	26-034532
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.4B	2023-12-31	2026-02-03	10-K	26-034532
26	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$526.0M	2023-12-31	2026-02-03	10-K	26-034532
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.6B	2022-12-31	2025-02-05	10-K	25-020826
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$548.0M	2022-12-31	2023-02-10	10-K	23-031250
29	depreciation amortization	us-gaap:Depreciation	$421.0M	2025-12-31	2026-02-03	10-K	26-034532

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

30	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$1.2B	2025-12-31	2026-02-03	10-K	26-034532
31	income tax	us-gaap:IncomeTaxExpenseBenefit	-$180.0M	2025-12-31	2026-02-03	10-K	26-034532
32	current assets	us-gaap:AssetsCurrent	$12.6B	2024-12-31	2026-02-03	10-K	26-034532
33	current liabilities	us-gaap:LiabilitiesCurrent	$12.8B	2024-12-31	2026-02-03	10-K	26-034532
34	assets	us-gaap:Assets	$43.5B	2023-12-31	2025-02-05	10-K	25-020826
35	assets	us-gaap:Assets	$42.1B	2023-09-30	2024-02-12	10-K	24-031005
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,149,812,898	2025-12-31	2026-02-03	10-K	26-034532
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,133,838,689	2024-12-31	2025-02-05	10-K	25-020826

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.